ANVS - Why Annovis Bio (ANVS) Stock Is Getting Hammered | Benzinga
Annovis Bio Inc (NYSE:ANVS) shares are trading lower by 20.6% to $9.24 during Wednesday’s session after the company announced a delay in the release of Phase III study data for buntanetap in Parkinson’s Disease.
What Else?
The postponement is attributed to ...
ANVS) Stock Is Getting Hammered>Full story available on Benzinga.com